Hypoglycemic Effects of Intestinal Electrical Stimulation by Enhancing Nutrient-Stimulated Secretion of GLP-1 in Rats
- 153 Downloads
To find out the best location for intestinal electrical stimulation (IES) to decrease hyperglycemia, and mechanisms involving intraluminal nutrients and plasma glucagon-like peptide-1 (GLP-1)
Materials and Methods
Eight rats had electrodes implanted at the duodenum and ileums for IES. The oral glucose tolerance test (OGTT) was performed with IES and sham-IES and with/without GLP-1 antagonist, exendin. To study the role of intraluminal nutrients, the experiment was repeated using intraperitoneal glucose tolerance test (IPGTT). Glucagon was administrated in the OGTT/IPGTT to induce temporary hyperglycemia.
(1) In the OGTT, IES at the duodenum reduced blood glucose from 30 to 120 min after oral glucose (P < 0.05, vs. sham-IES) and the hypoglycemic effect was more potent than IES at the ileum. (2) The hypoglycemic effect of IES was absent in IPGTT experiment, suggesting the important role of intraluminal nutrients. (3) An increase in GLP-1 was noted in the OGTT with IES at the duodenum in comparison with sham-IES. Moreover, the blocking effect of exendin suggested the role of GLP-1 in the hypoglycemic effect of IES.
The best stimulation location for IES to decrease hyperglycemia is in the duodenum. The hypoglycemic effect of IES is attributed to the enhancement in nutrient-stimulated release of GLP-1.
KeywordsIntestinal electrical stimulation Obesity Diabetes Glucagon-like peptide-1 Gastrointestinal motility Neuromodulation
This study was supported in part by a VA MERIT grant (1I01BX002010).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
A Statement of Animal Rights/Ethical Approval
All procedures in this study were approved by the Animal Care and Use Committee of the Veterans Affairs Medical Center (Oklahoma City, OK).
- 1.Pfeiffer AF, Klein HH. The treatment of type 2 diabetes. Dtsch Arztebl Int. 2014;111(5):69–81. quiz 82Google Scholar
- 9.Wan X, Yin J, Foreman R, et al. An optimized IES method and its inhibitory effects and mechanisms on food intake and body weight in diet-induced obese rats: IES for obesity. Obes Surg. 2017;27(12):3215–22.Google Scholar
- 16.Kawanami D, Matoba K, Sango K, et al. Incretin-based therapies for diabetic complications: basic mechanisms and clinical evidence. Int J Mol Sci. 2016;17(8).Google Scholar
- 18.Azami M, Sharifi A, Norozi S, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in patients with thalassemia major in Iran: a meta-analysis study. Caspian J Intern Med. 2017;8(1):1–15.Google Scholar
- 32.Vahl T, D'Alessio D. Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism. Curr Opin Clin Nutr Metab Care. 2003;6(4):461–8.Google Scholar
- 34.Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia. 1992;35(8):701–11.Google Scholar
- 41.Wootten D, Reynolds CA, Smith KJ, et al. Key interactions by conserved polar amino acids located at the transmembrane helical boundaries in class B GPCRs modulate activation, effector specificity and biased signalling in the glucagon-like peptide-1 receptor. Biochem Pharmacol. 2016;118:68–87.CrossRefGoogle Scholar
- 42.Nance KD, Days EL, Weaver CD, et al. Discovery of a novel series of orally bioavailable and CNS penetrant glucagon-like peptide-1 receptor (GLP-1R) noncompetitive antagonists based on a 1,3-disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione core. J Med Chem. 2017;60(4):1611–6.CrossRefGoogle Scholar